WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (29)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Uden, E.
Right arrow Articles by Masliah, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Uden, E.
Right arrow Articles by Masliah, E.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
Medline Plus Health Information
*Degenerative Nerve Diseases

 Previous Article  |  Next Article 

The Journal of Neuroscience, November 1, 2002, 22(21):9298-9304

Increased Extracellular Amyloid Deposition and Neurodegeneration in Human Amyloid Precursor Protein Transgenic Mice Deficient in Receptor-Associated Protein

Emily Van Uden1, Margaret Mallory1, Isaac Veinbergs1, Michael Alford1, Edward Rockenstein1, and Eliezer Masliah1, 2

Departments of 1 Neurosciences and 2 Pathology, University of California, San Diego, School of Medicine, La Jolla, California 92093-0624


    ABSTRACT

TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The low-density lipoprotein receptor-related protein (LRP) is an abundant neuronal cell surface receptor that regulates amyloid beta -protein (Abeta ) trafficking into the cell. Specifically, LRP binds secreted Abeta complexes and mediates its degradation. Previously, we have shown in vitro that the uptake of Abeta mediated by LRP is protective and that blocking this receptor significantly enhances neurotoxicity. To further characterize the effects of LRP and other lipoprotein receptors on Abeta deposition, an in vivo model of decreased LRP expression, receptor-associated protein (RAP)-deficient (RAP-/-) mice was crossed with human amyloid protein precursor transgenic (hAPP tg) mice, and plaque formation and neurodegeneration were analyzed. We found that, although the age of onset for plaque formation was the same in hAPP tg and hAPP tg/RAP-/- mice, the amount of amyloid deposited doubled in the hAPP tg/RAP-/- background. Moreover, these mice displayed increased neuronal damage and astrogliosis. Together, these results further support the contention that LRP and other lipoprotein receptors might be neuroprotective against Abeta toxicity and that this receptor might play an integral role in Abeta clearance.

Key words: amyloid beta  protein; amyloid precursor protein; apopoliprotein E; low-density lipoprotein receptor; receptor-associated protein; transgenic mice


    INTRODUCTION

TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The low-density lipoprotein receptor (LDL-R) family consists of cell surface receptors that internalize extracellular ligands for lysosomal degradation (Hussain et al., 1999; Herz and Strickland, 2001) and includes the LDL-R, apopoliprotein E receptor-2 (apoER2), very low-density lipoprotein receptor (VLDL-R), low-density lipoprotein receptor-related protein (LRP), and Megalin/gp330 (Herz and Beffert, 2000; Herz, 2001a). Altered functioning of members of this family has been proposed recently to play an important role in Alzheimer's disease (AD) (Herz and Beffert, 2000) because they bind apoE (Herz and Beffert, 2000) and are expressed by glial cells surrounding the plaques (Christie et al., 1996), in which they modulate the inflammatory response to amyloid (LaDu et al., 2000), and genetic polymorphisms are probably linked to increased susceptibility to AD (Helbecque et al., 2001). Among them, LRP might play an especially important role in AD pathogenesis because ligands of this receptor, such as amyloid precursor protein (APP) (Kounnas et al., 1995), apoE (Herz and Beffert, 2000), and alpha 2-macroglobulin (alpha 2M) (Borth, 1992), are genetic risk factors for AD (Goate et al., 1991; Saunders et al., 1993; Blacker et al., 1998) and are found in the amyloid plaques (Rebeck et al., 1995). Furthermore, levels of LRP decrease with age, and a polymorphism in exon 3 of the LRP gene (C776T) has been associated with increased risk for late onset AD (Kang et al., 1997, 2000). Moreover, LRP and other lipoprotein receptors might play a role in AD by influencing the clearance of amyloid beta -protein (Abeta ) and the processing of APP, both central to the pathogenesis of AD (Trommsdorff et al., 1998; Ulery et al., 2000; Rebeck et al., 2001). Abeta is one of the proteolytic products of APP metabolism generated from the concerted cleavage at the N- and C-terminal site of the molecule by beta  and gamma  secretase, respectively (Checler, 1995; Selkoe et al., 1996; Sinha et al., 2000; Huse and Doms, 2001). The mechanisms by which LRP and other lipoprotein receptors might regulate APP metabolism are under intense scrutiny (Kounnas et al., 1995). However, most recent studies point to a central role for LRP. For example, although binding of Kunitz protease inhibitor (KPI) containing isoforms of APP (APP751 and APP770) to LRP results in increased Abeta production, binding of Abeta to LRP ligands, such as alpha 2M or apoE, contributes to reduced Abeta levels (Qiu et al., 1999; Rebeck et al., 2001). Furthermore, the C-terminal site of APP interacts with LRP via the adapter protein Fe65 (Trommsdorff et al., 1998; Kinoshita et al., 2001). This ectodomain interaction might alter the endocytic process responsible for Abeta generation. Thus, alterations on LRP and other lipoprotein receptor functioning might contribute to AD by modifying the processing of APP and the production and clearance of Abeta (Herz and Beffert, 2000).

To better understand the role of LRP and other lipoprotein receptors in AD and APP metabolism in vivo, transgenic (tg) mice overexpressing mutant human APP (hAPP) under the platelet-derived growth factor (PDGF) B chain promoter (Mucke et al., 2000b) were crossed with receptor-associated, protein-deficient (RAP-/-) (Van Uden et al., 1999a) mice, and plaque formation and levels of Abeta 1-40 and Abeta 1-42 were evaluated. For these experiments, RAP-/- mice were selected because previous studies have shown that it is possible to reduce the levels of LRP and other lipoprotein receptors (Van Uden et al., 1999a; Veinbergs et al., 2001) by deleting the RAP gene and because the homozygous LRP knock-out model is lethal (Willnow et al., 1995).


    MATERIALS AND METHODS

TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Generation of transgenic mice. The generation of mice expressing hAPP from the PDGF promoter has been described previously (Mucke et al., 2000b). The hAPP tg line J9 selected for this study expresses an alternatively spliced minigene, hAPP, bearing the amyloidogenic V717F and K670M/N671L mutations that have been linked to familial AD (Games et al., 1995). The line has been maintained by crossing heterozygous transgenic mice with nontransgenic (C57BL/6J × DBA/2) F1 breeders. The generation (Willnow et al., 1995) and further characterization (Van Uden et al., 1999a; Veinbergs et al., 2001) of RAP-/- mice on a C57BL/6 × 129 hybrid background have also been described. Compared with mice expressing endogenous RAP (RAP+/+), RAP-/- mice were selected because previous studies have shown that it is possible to reduce the levels of LRP and other lipoprotein receptors by 75% by deleting the RAP gene (Willnow et al., 1995; Veinbergs et al., 2001) and because the homozygous LRP knock-out model is lethal (Willnow et al., 1995). Interestingly, although RAP-/- mice do not exhibit any gross alterations (Willnow et al., 1995; Umans et al., 1999; Van Uden et al., 1999a), they are difficult to breed (Umans et al., 1999) and display significant age-related alterations in somatostatin-expressing neurons, accompanied by performance deficits in the water maze (Van Uden et al., 1999a). Deletion of the RAP gene results in reduced trafficking of LRP and other lipoprotein receptors to the plasma membrane because this 39 kDa chaperone molecule (Bu, 2001) facilitates the trafficking of lipoprotein receptors to the membrane (Bu et al., 1995; Willnow et al., 1996). Heterozygous hAPP transgenic mice (hAPP+/- tg) were crossed with homozygous RAP knock-out (RAP-/-) mice, and the resulting offspring (hAPP+/- tg/RAP+/-) were intercrossed to obtain the genotypes used in this study. The resulting groups of littermates contained comparable random mixtures of the C57BL/6, DBA/2, and 129 strains. All mice used in this study were wild type for the mouse APP gene. Genomic DNA was extracted from tail biopsies and analyzed by PCR for the presence of the hAPP transgene (Mucke et al., 2000b) and the endogenous RAP gene (Van Uden et al., 1999a).

Tissue processing. Mice were killed by transcardiac saline perfusion under anesthesia with chloral hydrate; brains were removed and divided sagitally. The right hemibrain was snap frozen and stored at -70°C for RNA or protein analysis (Van Uden et al., 1999b), and the left was drop fixed in phosphate-buffered 4% paraformaldehyde at 4°C for 48 hr and serially sectioned sagitally at 40 µm with the Vibratome 2000 (Leica, Deerfield, IL) for neuropathological analysis (Van Uden et al., 1999a; Veinbergs et al., 2001).

RNA extraction and analysis. Total RNA from snap-frozen hemibrains or dissected brain regions (neocortex and hippocampus) was isolated with Tri-reagent (Molecular Research Center, Cincinnati, OH) and stored in Formazol buffer (Molecular Research Center) at -20°C. Total RNA (10 µg/sample) was analyzed by solution hybridization RNase protection assay as described previously (Van Uden et al., 1999b). Samples were separated on 5% acrylamide-8 M urea Tris-borate-EDTA gels, and dried gels were exposed to Kodak XAR film (Eastman Kodak, Rochester, NY). mRNA levels were quantitated from PhosphorImager readings of probe-specific signals corrected for RNA content-loading errors by normalization to beta -actin signals. The following 32P-labeled antisense riboprobes were used to identify specific mRNAs [protected nucleotides (nt) (GenBank accession number)]: hAPP [nt 780-1009 (accession number NM  000484) of hAPP exon 6], murine APP (mAPP) [nt 702-881 (accession number X59379) of mAPP exon5], and mbeta -actin [nt 480-565 (accession number X03672) of mouse beta -actin mRNA].

Western blot analysis. Levels of RAP, LRP, LDL-R, and hAPP expression in the brain were assessed by Western blot, as described previously (Van Uden et al., 1999b; Veinbergs et al., 2001). Briefly, aliquots from cytosolic and particulate fractions assayed by the Lowry method were loaded (15 µg/lane) into SDS-PAGE gels (10%) and then blotted onto nitrocellulose paper. Blots were incubated with rabbit polyclonal antibodies against RAP (1:20,000) and LRP (1:1000, both courtesy of Dr. Robert Orlando, University of New Mexico, Alburquerque, NM) and the mouse monoclonal antibodies against LDL-R (Calbiochem, San Diego, CA) (1:1000) and hAPP (8E5; 1:10,000; courtesy of Elan Pharmaceuticals, South San Francisco, CA), followed by 125I-protein A. Finally, blots were exposed to PhosphorImager (Molecular Dynamics, Sunnyvale, CA) screens and analyzed with ImageQuant software (Molecular Dynamics).

Detection of Abeta deposits. Vibratome sections were incubated overnight at 4°C with the biotinylated mouse monoclonal antibody 3D6 (1:600; courtesy of Elan Pharmaceuticals), which specifically recognizes Abeta . Binding of primary antibody was detected with the Vector Laboratories (Burlingame, CA) Elite kit using diaminobenzidine (DAB)-H2O2 for development. Sections were counterstained with 1% hematoxylin and examined with a Vanox light microscope (Olympus Optical, Tokyo, Japan) using a 2.5× objective. The percentage area of the hippocampus covered by 3D6-immunoreactive (IR) material ("plaque load") was determined with the Quantimet 570C as described previously (Mucke et al., 2000a,b). Three immunolabeled sections were analyzed per mouse, and the average of the individual measurements was used to calculate group means.

Some sections were double immunolabeled with the rabbit polyclonal antibody against Abeta [R1280; 1:500; courtesy of Dr. Dennis Selkoe (Brigham and Women's Hospital, Harvard University, Boston, MA)] (Joachim et al., 1991) and either phosphorylated neurofilaments (SMI 312; 1:1000; Sternberger Monoclonals, Baltimore, MD) or phosphorylated tau (AT8; 1:100; Innogenetics, Norcross, GA), as described previously (Mucke et al., 2000b). Sections were analyzed with the laser scanning confocal microscope (LSCM), and serial optical z-sections (0.2 µm thick) of the double-immunolabeled neuritic plaques were collected from each region using the dual-channel imaging capability of the confocal microscope (Mucke et al., 2000b). The Texas Red channel collected the R1280-immunolabeled amyloid deposits, and the fluorescein isothiocyanate (FITC) channel collected the corresponding images of the SMI312- or AT8-immunolabeled elements in the plaques.

Determinations of Abeta by ELISA. Briefly, as described previously (Rockenstein et al., 2001), brain samples of human or mouse cortex were homogenized in an ice-cold buffer containing 5 M guanidine-HCl and PBS containing 1× protease inhibitor cocktail (Calbiochem), pH 8.0. The homogenate was then mixed for 3-4 hr at room temperature and centrifuged at 16,000 × g for 20 min at 4°C. The supernatant was diluted 10-fold in Dulbecco's PBS, pH 7.4, containing 5% bovine serum albumin and 0.03% Tween 20. Quantification of Abeta 1-40 and Abeta 1-42 in the diluted brain homogenates was performed with a commercially available sandwich-type ELISA for Abeta 1-40 and Abeta 1-42 (Biosource, Camarillo, CA).

Analysis of neurodegeneration. To determine whether the alterations in APP metabolism in the hAPP tg/RAP-/- were associated with increased neurodegeneration, vibratome brain sections were immunostained with the mouse monoclonal antibodies against glial fibrillary acidic protein (GFAP) (1:500; marker of astrogliosis in response to neuronal injury; Chemicon, Temecula, CA) or microtubule-associated proteins (MAP2) (1:10; marker of dendrites; Chemicon) as described previously (Hsia et al., 1999; Rockenstein et al., 2001). For GFAP, sections were processed by standard immunoperoxidase techniques using the avidin-biotin complex Elite kit (Vector Laboratories) with DAB. For each case, sections were immunolabeled in duplicate and analyzed with the Quantimet 570C to determine the levels of GFAP immunoreactivity (corrected optical density) in the neocortex and hippocampus.

For anti-MAP2 (1:10; Chemicon), sections were incubated overnight, followed by incubation with FITC-conjugated horse anti-mouse IgG (1:75; Vector Laboratories). Sections were then transferred to SuperFrost slides (Fisher Scientific, Houston, TX), mounted under glass coverslips with anti-fading medium (Vector Laboratories), and imaged with the LSCM, as described previously (Mucke et al., 2000b). For each experiment, we first determined the linear range of the fluorescence intensity of immunoreactive dendrites in non-tg control sections. This setting was then used to collect all images analyzed in the same experiment. For each mouse, 12 confocal images (four per section) of the neocortex and caudate-putamen, each covering an area of 7282 µm2, were obtained. Digitized images were transferred to a Macintosh computer (Apple Computers, Cupertino, CA) and analyzed with NIH Image 1.43 software. The area occupied by MAP2-IR dendrites was quantified and expressed as a percentage of the total image area (Mucke et al., 2000b). This method of quantifying MAP2-IR dendrites has been used extensively to assess neurodegenerative alterations in diverse experimental models and in diseased human brains. It has also been validated previously by comparisons with quantitative immunoblots and modifications of the stereological "dissector" approach. To ensure objective assessments and reliability of results, all sections in any given experiment were blind coded and processed in parallel.

Statistical analyses. For all studies described, mice were coded to ensure objective assessment, and codes were not broken until the analysis was complete. Statistical analyses were performed with the StatView 5.0 program (SAS Institute, Cary, NC). Differences among means were assessed by one-way ANOVA followed, as indicated, by Dunnett's or Tukey-Kramer post hoc tests. Correlation studies were performed by simple regression analysis. The null hypothesis was rejected at the 0.05 level.


    RESULTS

TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Generation of hAPP tg mice lacking murine RAP

To study in vivo the influence of LRP and other lipoprotein receptors on amyloid deposition and other AD-related neuropathology, we bred RAP-/- mice with hAPP tg mice. These crosses yielded the following groups of mice: (1) non-tg expressing the endogenous mRAP (RAP+/+) (n = 15, 10 months; n = 14, 18 months), (2) non-tg lacking endogenous mRAP (RAP-/-) (n = 8, 10 months; n = 8, 18 months), (3) hAPP tg expressing both copies of the endogenous mRAP (n = 15, 10 months; n = 14, 18 months), and (4) hAPP tg lacking endogenous mRAP (n = 5, 10 months; n = 5, 18 months) (hAPP tg/RAP-/-). Levels of hAPP expression were comparable in both groups of tg mice lacking or expressing endogenous RAP (Fig. 1A,B). Furthermore, levels of mAPP expression were unchanged among the four groups (Fig. 1A,B). Western blot analysis confirmed that hAPP expression levels were comparable in both groups of tg mice lacking or expressing endogenous RAP (Fig. 1C,D). Moreover, in both hAPP tg and non-tg mice bred on the RAP-/- background, levels of LRP immunoreactivity were similarly reduced by ~80% (Fig. 1C,D). LDL-R immunoreactivity levels were reduced in both RAP-/- groups by ~40% (data not shown). Patterns of hAPP immunoreactivity (Fig. 2A-D) were unchanged in mice expressing endogenous mRAP (Fig. 2E,F) compared with mice in which this chaperone protein was deleted (Fig. 2G,H). Consistent with the Western blot analysis, immunocytochemical analysis with an LRP antibody showed that, compared with non-tg and hAPP tg mice (Fig. 2I,J), mice bred on the RAP-/- background display a similar reduction in levels and patterns of LRP immunoreactivity (Fig. 2K,L).



View larger version (48K):
[in this window]
[in a new window]
  		Figure 1.   Characterization of APP and LRP expression in hAPP tg/RAP-/- mice. A, Ribonuclease protection assay. A total of four mice per group was analyzed. Representative autoradiogram for mAPP and hAPP is shown. The leftmost lane represents the undigested (U) radiolabeled probes; the other lanes contain the same riboprobes plus brain RNA samples digested with RNases. Protected mRNAs are indicated on the right. The hAPP, mAPP, and actin mRNA bands were detected as fragments of 230, 180, and 85 nt, respectively. B, Analysis of levels of hAPP and mAPP mRNA expression in tg mice; results are expressed as a ratio of APP to actin. Error bars are mean ± SEM. C, Western blot analysis with antibodies against hAPP and LRP. The hAPP-specific antibody identified a broad band at an approximate molecular weight (MW) of 110 kDa. The specific antibody against the C-terminal region of LRP detected a band at an approximate MW of 85 kDa. D, Analysis of hAPP and LRP immunoreactivity; results are expressed as integrated pixel intensity. Error bars are mean ± SEM.



View larger version (76K):
[in this window]
[in a new window]
  		Figure 2.   Immunocytochemical analysis of hAPP, RAP, and LRP expression in hAPP tg/RAP-/- mice. A-D, hAPP immunoreactivity with the 8E5 monoclonal antibody; E-H, RAP immunoreactivity in the frontal cortex of 18-month-old mice; I-L, LRP immunoreactivity in the frontal cortex of 18-month-old mice. A, No hAPP immunoreactivity was observed in non-tg mice. B, hAPP tg mice displayed immunostaining of a subset of pyramidal neurons in the neocortex. C, No hAPP immunoreactivity was observed in RAP-/- mice. D, hAPP tg/RAP-/- tg mice hAPP-immunoreactive pyramidal neurons in the neocortex. E, Non-tg; F, hAPP tg mice showed extensive immunostaining of pyramidal neurons in the neocortex. In the RAP-/- (G) and hAPP tg/RAP-/- (H), no RAP immunoreactivity was observed. Non-tg (I) and hAPP tg (J) mice showed extensive LRP immunostaining of pyramidal neurons in the neocortex. In the RAP-/- (G) and hAPP tg/RAP-/- (H), no LRP levels of LRP immunoreactivity were decreased. Scale bar, 25 µm.

Increased Abeta deposition in hAPP tg/RAP-/- tg mice

Cerebral deposition of Abeta was compared in all four groups of mice at 10 and 18 months of age. No amyloid deposits were detected in non-tg controls (Fig. 3A) and in RAP-/- mice (Fig. 3C). In contrast, hAPP tg (Fig. 3B,I,J) and hAPP tg/RAP-/- mice (Fig. 3D,H,L) developed typical AD-like plaques at ~10 months of age, with progressive accumulation of plaques observed at 18 months of age (Fig. 4A). At both ages analyzed, hAPP tg/RAP-/- mice had a higher plaque load than hAPP tg mice (Fig. 4A). Compared with non-tg control (Fig. 3M) and RAP-/- (Fig. 3O) mice, hAPP tg (Fig. 3N) and hAPP tg/RAP-/- mice (Fig. 3P) developed reactive astrocytosis that was most prominent at 18 months of age (Fig. 4C).



View larger version (125K):
[in this window]
[in a new window]
  		Figure 3.   Patterns of Abeta immunoreactivity in hAPP tg/RAP-/-. A-D, Abeta immunoreactivity in the neocortex; E-H, low-power view (60×) of the hippocampal dentate gyrus; I-L, higher-power view (200×) of the dentate gyrus; M, P, GFAP immunoreactivity in the hippocampus. All images are from 18-month-old mice. A, No Abeta deposits were observed in non-tg controls. B, Mature and diffuse amyloid plaques in hAPP tg/RAP tg mice. C, No Abeta deposits were observed in RAP-/- mice. D, hAPP tg/RAP-/- mice displayed increased Abeta immunoreactive plaques. Scale bar, 20 µm. E, I, No Abeta deposits were observed in the molecular layer of the dentate in non-tg controls. F, J, Abundant diffuse amyloid plaques in hAPP tg mice. G, K, No Abeta deposits were observed in RAP-/- mice. H, L, hAPP tg/RAP-/- mice displayed increased Abeta deposits in the molecular layer of the dentate. Scale bar, 60 µm. M, Mild astrogliosis in non-tg mice. N, Increased astroglial reaction in hAPP mice. O, Mild astroglial immunostaining in RAP-/- mice. P, Enhanced astroglial reaction in hAPP tg/RAP-/- mice. Scale bar, 30 µm.



View larger version (41K):
[in this window]
[in a new window]
  		Figure 4.   Quantitative analysis of amyloid production and neurodegeneration. A, Determination of percentage area of the neuropil occupied by Abeta immunoreactive deposits in the frontal cortex and hippocampus. B, Determination of Abeta levels in the hippocampus by ELISA in 10- and 18-month-old mice. *p < 0.05, different by two-tailed unpaired t test when compared with hAPP tg mice. C, Densitometrical analysis of GFAP immunoreactivity in the hippocampus using the Quantimet 570C in 10- and 18-month-old mice. *p < 0.05 different from non-tg control by one-way ANOVA post hoc Dunnet's test. D, Levels of MAP2-IR in the outer molecular layer of the dentate gyrus in 10- and 18-month-old mice. *p < 0.05, different by one-way ANOVA post hoc Dunnet's test.

The increased amyloid deposition in the hAPP tg/RAP-/- mice could be because of effects of LRP and other lipoprotein receptors on the production, removal, or aggregation of Abeta . RAP expression did not affect cerebral hAPP mRNA or protein expression (Fig. 1A,B) or the characteristics of the plaques; however, the levels of Abeta 1-42 in the hippocampus were elevated (Fig. 4B). Thus, the amyloidogenic effect of LRP and other lipoprotein receptors appears to result from decreased Abeta clearance rather than from increased expression of the hAPP transgene or increased Abeta production.

Because loss of synaptic connections and dendritic damage is associated with cognitive deficits in AD (DeKosky and Scheff, 1990; Terry et al., 1991; Zhan et al., 1993; Dickson et al., 1995) and in hAPP tg mice (Hsia et al., 1999; Mucke et al., 2000b), we analyzed the levels MAP2 immunoreactivity (dendritic marker) in the hippocampus as an indicator of neurodegeneration. Compared with non-tg controls (Figs. 4D, 5A,E), RAP-/- mice expression had normal levels of MAP2-IR dendrites (Figs. 4D, 5C,G), indicating that decreased expression of LRP does not by itself affect the integrity of these structures. In contrast, hAPP tg mice had decreased levels of MAP2 immunoreactivity (Figs. 4C, 5B,F), and the absence of RAP in these mice resulted in additional decreases in the levels of MAP2 immunoreactivity (Figs. 4C, 5D,H).



View larger version (81K):
[in this window]
[in a new window]
  		Figure 5.   Patterns of dendritic degeneration in hAPP tg/RAP-/-. Sections from 18-month-old mice were immunolabeled with an antibody against MAP2 and imaged with the laser scanning confocal microscope. A-D, Neocortex; E-H, molecular layer of the hippocampal dentate gyrus. Scale bar, 20 µm.


    DISCUSSION

TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The present study showed that decreased expression of LRP and other lipoprotein receptors resulted in increased amyloid deposition and neurodegeneration in hAPP tg/RAP -/- mice. These results are consistent with previous studies showing that, in AD, amyloid deposition correlates with decreased LRP activity and supports the possibility that LRP might regulate Abeta clearance (Kang et al., 2000). Because previous studies have proposed that LRP might be centrally involved in the pathogenesis of AD (Herz and Beffert, 2000; Ulery et al., 2000) and LRP might be the main receptor responsible for Abeta endocytosis (Narita et al., 1997b; Qiu et al., 1999), we hypothesized that the alterations observed in the hAPPtg/RAP-/- mice were probably most closely associated with altered functioning of LRP. Nevertheless, in addition to LRP, it is important to note that RAP also regulates the trafficking of other lipoprotein receptors, such as LDL-R, VLDL-R, and apoER2, albeit to a lesser extent (Herz et al., 1991; Bu, 1998, 2001). Thus, we cannot completely rule out the possibility that decreased expression of other receptors in the RAP-/- mice might also play a role increasing Abeta deposition. However, it is worth noting that, in the RAP-/- mice, LRP levels are reduced by 75-80%, whereas levels of LDL-R and VLDL-R are reduced by 40-50% (Veinbergs et al., 2001). In addition, LRP appears to be the main lipoprotein receptor responsible for Abeta clearance (Narita et al., 1997b; Qiu et al., 1999), suggesting that, in the hAPP tg/RAP-/- mice, the effects of other RAP-dependent receptors on Abeta deposition might be less critical. However, future studies crossing hAPPtg mice with VLDL-R-/-, apoER2 -/-, or LDL-R-/- mice will be necessary to investigate this possibility.

Increased Abeta deposition in the hAPP tg/RAP-/- model could be the result of increased Abeta production or decreased Abeta clearance by lipoprotein receptors. Increased Abeta production could result from increased hAPP synthesis or cleavage by beta  and gamma  secretases. However, because hAPP levels were not affected in the hAPP tg/RAP-/-, we concluded that the most likely cause for the increased Abeta deposition could be a decrease in Abeta clearance by lipoprotein receptors. This is supported by studies showing that Abeta 40 and Abeta 42 bound to alpha 2M is cleared by LRP for subsequent degradation (Kang et al., 2000), and blocking LRP with RAP significantly decreased alpha 2M-dependent Abeta clearance in primary neuronal cultures and glial cells (Narita et al., 1997a; Fabrizi et al., 1999; Qiu et al., 1999). Furthermore, Abeta binding to other LRP ligands, such as apoE, also contributes to reduced Abeta levels (Kang et al., 2000; Shibata et al., 2000; Herz and Strickland, 2001). Alternatively, reduced LRP levels may promote increased amyloid deposition in hAPP tg/RAP-/- mice by impeding the clearance of apoE, alpha 2M, and lactoferrin because all of these LRP ligands also sequester Abeta and mediate its clearance (Narita et al., 1997a; Yang et al., 1999; Kang et al., 2000). However, this possibility is less likely because altered expression of apoE in crosses between hAPP tg and apoE-deficient (Bales et al., 1997) or apoE tg (Irizarry et al., 2000) mice results in delayed amyloid deposition and redistribution of Abeta in the hippocampus that differs considerably with our observations in the hAPP tg/RAP-/- mice.

Other receptors involved in Abeta clearance include the receptor for advanced glycation end products (RAGE), scavenger receptor type A (SR-A) (Paresce et al., 1996; Yan et al., 1996; El Khoury et al., 1998), and the G-protein-coupled receptor formyl peptide receptor like-1 (FPRL1) (Yazawa et al., 2001). Some interesting differences exist among these Abeta receptors. For example, LRP is found primarily in neurons, and Abeta binding is dependent on coupling to alpha 2M, apoE, and apoJ (Herz, 2001b). In contrast, RAGE, SR-A, and FPRL1 are primarily found in macrophages, and Abeta binds to them as a free peptide (Shibata et al., 2000; Yazawa et al., 2001). Furthermore, RAGE and SR-A mediate brain endocytosis and transcytosis of Abeta , whereas LRP mediates blood-brain barrier transport of plasma Abeta complexed to apoJ (Shibata et al., 2000). It is unclear how these receptors regulate Abeta levels in concert. However, no significant effects on Abeta deposition were observed in previous studies in which hAPP tg mice were crossed with SR-deficient mice (Huang et al., 1999). Together, these results suggest that in vivo lipoprotein receptor-mediated Abeta clearance is central to amyloid deposition. Additional studies in vivo in our models and others looking at circulating Abeta levels are warranted for additional clues into the clearance of Abeta . Although our in vivo model results in the decreased expression of LRP and other lipoprotein receptors and recent studies in vitro and in AD brains suggests that decreased LRP levels are associated with decreased Abeta clearance (Kang et al., 2000), the precise mechanisms by which LRP regulates Abeta levels are complex and remain controversial. For example, in human neuroglioma (H4) cells, lack of LRP activity results in decreased Abeta production, whereas the presence of functional LRP is associated with increased production and secretion of Abeta (Ulery et al., 2000). Long-term treatment with RAP results in increased levels of both cell surface APP and secreted APP alpha , along with decreased Abeta production (Ulery et al., 2000). These effects might be the result of direct interactions between APP and LRP, because fluorescence resonance energy transfer experiments have shown that there is a close opposition of the extracellular domains of KPI-containing APP and LRP that is RAP sensitive (Kinoshita et al., 2001). The association of LRP with forms of APP that contain the KPI domain alters APP processing, leading to altered Abeta production (Kinoshita et al., 2001). APP-LRP interactions in CHO cells have shown that decreased LRP activity by genetic deletion or by addition of exogenous RAP could result in decreased Abeta production from hAPP770-transfected cells, and these ectodomain interactions alter the endocytic pathway (Kinoshita et al., 2001). Together, these studies suggest that LRP might influence Abeta metabolism by different mechanisms, including direct interactions with APP, as well as internalization and clearance of Abeta bound to alpha 2M.

The present study also showed that decreased expression of LRP and other lipoprotein receptors resulted in greater synaptic damage in the hAPP tg/RAP-/- mice. This is consistent with previous studies showing that LRP expressed by neurons has the capacity to signal and may be involved in long-term potentiation (LTP) and in regulating synaptic plasticity (Herz and Strickland, 2001). Perfusion of hippocampal slices with RAP reduced late-phase LTP. In addition, RAP also blocked the enhancing effect of synaptic potentiation by exogenous application of the LRP ligand tissue type plasminogen activator (tPA) in hippocampal slices prepared from tPA knock-out mice, indicating that interactions between tPA and cell surface LRP are important for synaptic plasticity (Zhuo et al., 2000). Furthermore, RAP-/- mice display deficient somatostatin release and memory deficits in the water maze (Van Uden et al., 1999a) that are ameliorated by another LRP ligand, namely apoE (Veinbergs et al., 2001). In addition, previous studies have shown that, in the presence of alpha 2M, LRP protects neural cell lines against the neurotoxic effects of Abeta (Fabrizi et al., 1999; Van Uden et al., 1999b, 2000). These effects were blocked by exogenous administration of RAP and are dependent on calcium/calmodulin-dependent kinase 2 signaling (Van Uden et al., 2000). In hAPP tg mice, previous studies have shown that Abeta is synaptotoxic (Mucke et al., 2000b) and disrupts synaptic transmission independently of plaque formation (Hsia et al., 1999). Together, these studies suggest that LRP and its ligands might protect neurons against the neurotoxic effects of Abeta by facilitating Abeta clearance.

In summary, the present study showed that decreased Abeta clearance in hAPP tg/RAP-/- mice results in increased amyloid deposition and dendritic damage, supporting the contention that decreased expression of LRP and other lipoprotein receptors might play an important role in the pathogenesis of AD and that increasing LRP activity might represent a novel modality for treatment of AD.


    FOOTNOTES

Received April 19, 2002; revised July 23, 2002; accepted Aug. 14, 2002.

This work was supported by National Institutes of Health Grants AG5131, AG10689, and AG18440 and by a grant from the M. J. Fox Foundation for Parkinson's Research. We thank Dr. Lennart Mucke for his helpful comments and providing the hAPP tg mice for these experiments.

Correspondence should be addressed to Dr. E. Masliah, Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093-0624. E-mail: emasliah{at}ucsd.edu.


    REFERENCES

TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

  • Bales K, Verina T, Dodel R, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone E, Little S, Cummins D, Piccardo P, Ghetti B, Paul S (1997) Lack of apolipoprotein E dramatically reduces amyloid beta -peptide deposition. Nat Genet 17:263-264[Web of Science][Medline].
  • Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, Perry R, Watson Jr B, Bassett SS, McInnis MG, Albert MS, Hyman BT, Tanzi RE (1998) Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 19:357-360[Web of Science][Medline].
  • Borth W (1992) Alpha 2-macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J 6:3345-3353[Abstract].
  • Bu G (1998) Receptor-associated protein: a specialized chaperone and antagonist for members of the LDL receptor gene family. Curr Opin Lipidol 9:149-155[Web of Science][Medline].
  • Bu G (2001) The roles of receptor-associated protein (RAP) as a molecular chaperone for members of the LDL receptor family. Int Rev Cytol 209:79-116[Web of Science][Medline].
  • Bu G, Geuze H, Strous G, Schwartz A (1995) 39 kDa receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein. EMBO J 14:2269-2280[Web of Science][Medline].
  • Checler F (1995) Processing of the beta -amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem 65:1431-1444[Web of Science][Medline].
  • Christie RH, Chung H, Rebeck GW, Strickland D, Hyman BT (1996) Expression of the very low-density lipoprotein receptor (VLDL-r), an apolipoprotein-E receptor, in the central nervous system and in Alzheimer's disease. J Neuropathol Exp Neurol 55:491-498[Web of Science][Medline].
  • DeKosky S, Scheff S (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 27:457-464[Web of Science][Medline].
  • Dickson D, Crystal H, Bevona C, Honer W, Vincent I, Davies P (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16:285-304[Web of Science][Medline].
  • El Khoury J, Hickman SE, Thomas CA, Loike JD, Silverstein SC (1998) Microglia, scavenger receptors, and the pathogenesis of Alzheimer's disease. Neurobiol Aging 19:S81-S84[Web of Science][Medline].
  • Fabrizi C, Businaro R, Lauro G, Starace G, Fumagalli L (1999) Activated alpha2-microglobulin increases beta -amyloid (25-35)-induced toxicity in LAN5 human neuroblastoma cells. Exp Neurol 155:252-259[Medline].
  • Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemes J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta -amyloid precursor protein. Nature 373:523-527[Medline].
  • Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, Guiffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Williamson R, Rossor M, Owen M, Hardy J (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704-706[Medline].
  • Helbecque N, Berr C, Cottel D, Fromentin-David I, Sazdovitch V, Ricolfi F, Ducimetiere P, Di Menza C, Amouyel P (2001) VLDL receptor polymorphism, cognitive impairment, and dementia. Neurology 56:1183-1188[Abstract/Free Full Text].
  • Herz J (2001a) The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron 29:571-581[Web of Science][Medline].
  • Herz J (2001b) Lipoprotein receptors: beacons to neurons? Trends Neurosci 24:193-195[Medline].
  • Herz J, Beffert U (2000) Apolipoprotein E receptors: linking brain development and Alzheimer's disease. Nat Rev Neurosci 1:51-58[Web of Science][Medline].
  • Herz J, Strickland DK (2001) LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 108:779-784[Web of Science][Medline].
  • Herz J, Goldstein J, Strickland D, Ho Y, Brown M (1991) The 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J Biol Chem 266:21232-21238[Abstract/Free Full Text].
  • Hsia AY, Masliah E, McConlogue L, Yu G-Q, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96:3228-3233[Abstract/Free Full Text].
  • Huang F, Buttini M, Wyss-Coray T, McConlogue L, Kodama T, Pitas RE, Mucke L (1999) Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors. Am J Pathol 155:1741-1747[Abstract/Free Full Text].
  • Huse JT, Doms RW (2001) Neurotoxic traffic: uncovering the mechanics of amyloid production in Alzheimer's disease. Traffic 2:75-81[Medline].
  • Hussain MM, Strickland DK, Bakillah A (1999) The mammalian low-density lipoprotein receptor family. Annu Rev Nutr 19:141-172[Web of Science][Medline].
  • Irizarry MC, Cheung BS, Rebeck GW, Paul SM, Bales KR, Hyman BT (2000) Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice. Acta Neuropathol (Berl) 100:451-458[Medline].
  • Joachim C, Games D, Morris J, Ward P, Frenkel D, Selkoe D (1991) Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques. Am J Pathol 138:373-384[Abstract].
  • Kang D, Saitoh T, Chen X, Xia Y, Masliah E, Hansen L, Thomas R, Thal L, Katzman R (1997) Genetic association of the low density lipoprotein receptor related protein gene (LRP), an apoE receptor, with late-onset Alzheimer's disease. Neurology 49:56-61[Abstract/Free Full Text].
  • Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH (2000) Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 106:1159-1166[Web of Science][Medline].
  • Kinoshita A, Whelan CM, Smith CJ, Mikhailenko I, Rebeck GW, Strickland DK, Hyman BT (2001) Demonstration by fluorescence resonance energy transfer of two sites of interaction between the low-density lipoprotein receptor-related protein and the amyloid precursor protein: role of the intracellular adapter protein Fe65. J Neurosci 21:8354-8361[Abstract/Free Full Text].
  • Kounnas M, Moir R, Rebeck G, Bush A, Argaves W, Tanzi R, Hyman B, Strickland D (1995) LDL receptor-related protein, a multifunctional apoE receptor, binds secreted beta -amyloid precursor protein and mediates its degradation. Cell 82:331-340[Web of Science][Medline].
  • LaDu MJ, Shah JA, Reardon CA, Getz GS, Bu G, Hu J, Guo L, van Eldik LJ (2000) Apolipoprotein E receptors mediate the effects of beta-amyloid on astrocyte cultures. J Biol Chem 275:33974-33980[Abstract/Free Full Text].
  • Mucke L, Yu GQ, McConlogue L, Rockenstein EM, Abraham CR, Masliah E (2000a) Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. Am J Pathol 157:2003-2010[Abstract/Free Full Text].
  • Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein E, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000b) High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050-4058[Abstract/Free Full Text].
  • Narita M, Bu G, Holtzman D, Schwartz A (1997a) The low-density lipoprotein receptor-related protein, a multifunctional apolipoprotein E receptor, modulates hippocampal neurite development. J Neurochem 68:587-595[Web of Science][Medline].
  • Narita M, Holtzman DM, Schwartz AL, Bu G (1997b) Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem 69:1904-1911[Web of Science][Medline].
  • Paresce DM, Ghosh RN, Maxfield FR (1996) Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 17:553-565[Web of Science][Medline].
  • Qiu Z, Strickland DK, Hyman BT, Rebeck GW (1999) Alpha2-macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem 73:1393-1398[Web of Science][Medline].
  • Rebeck G, Harr S, Strickland D, Hyman B (1995) Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol 37:211-217[Web of Science][Medline].
  • Rebeck GW, Moir RD, Mui S, Strickland DK, Tanzi RE, Hyman BT (2001) Association of membrane-bound amyloid precursor protein APP with the apolipoprotein E receptor LRP. Mol Brain Res 87:238-245[Medline].
  • Rockenstein E, Mallory M, Mante M, Sisk A, Masliah E (2001) Early formation of mature amyloid-b proteins deposits in a mutant APP transgenic model depends on levels of Ab1-42. J Neurosci Res 66:573-582[Web of Science][Medline].
  • Saunders A, Strittmatter W, Schmechel D, St. George-Hyslop P, Pericak-Vance M, Joo S, Rosi B, Gusella J, Crapper-MacLachlan D, Alberts M, Hulette C, Crain B, Goldgaber D, Roses A (1993) Association of apolipoprotein E allele E4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43:1467-1472[Abstract/Free Full Text].
  • Selkoe DJ, Yamazaki T, Citron M, Podlisny MB, Koo EH, Teplow DB, Haass C (1996) The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann NY Acad Sci 777:57-64[Web of Science][Medline].
  • Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489-1499[Web of Science][Medline].
  • Sinha S, Anderson J, John V, McConlogue L, Basi G, Thorsett E, Schenk D (2000) Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann NY Acad Sci 920:206-208[Medline].
  • Terry R, Masliah E, Salmon D, Butters N, DeTeresa R, Hill R, Hansen L, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572-580[Web of Science][Medline].
  • Trommsdorff M, Borg J, Margolis B, Herz J (1998) Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J Biol Chem 273:33556-33560[Abstract/Free Full Text].
  • Ulery P, Beers J, Mikhailenko I, Tanzi R, Rebeck G, Hyman B, Strickland D (2000) Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem 275:7410-7415[Abstract/Free Full Text].
  • Umans L, Overbergh L, Serneels L, Tesseur I, Van Leuven F, Group EG (1999) Analysis of expression of genes involved in apolipoprotein E-based lipoprotein metabolism in pregnant mice deficient in the receptor-associated protein, the low density lipoprotein receptor, or apolipoprotein E. Biol Reprod 61:1216-1225[Abstract/Free Full Text].
  • Van Uden E, Veinbergs I, Mallory M, Orlando R, Masliah E (1999a) A novel role for receptor-associated protein in somatostatin modulation: implications for Alzheimer's disease. Neuroscience 88:687-700[Web of Science][Medline].
  • Van Uden E, Carlson G, St. George-Hyslop P, Westaway D, Orlando R, Mallory M, Rockenstein E, Masliah E (1999b) Aberrant Presenilin-1 expression downregulates LDL receptor-related protein (LRP): is LRP central to Alzheimer's disease pathogenesis? Mol Cell Neurosci 14:129-140[Medline].
  • Van Uden E, Sagara Y, Van Uden J, Orlando R, Mallory M, Rockenstein E, Masliah E (2000) A protective role of the low density lipoprotein receptor-related protein against amyloid beta -protein toxicity. J Biol Chem 275:30525-30530[Abstract/Free Full Text].
  • Veinbergs I, Van Uden E, Mallory M, Alford M, McGiffert C, DeTeresa R, Orlando R, Masliah E (2001) Role of apolipoprotein E receptors in regulating the differential in vivo neurotrophic effects of apolipoprotein E. Exp Neurol 170:15-26[Medline].
  • Willnow T, Armstrong S, Hammer R, Herz J (1995) Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci USA 92:4537-4541[Abstract/Free Full Text].
  • Willnow T, Rohlmann A, Horton J, Otani H, Braun J, Hammer R, Herz J (1996) RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors. EMBO J 15:2632-2639[Web of Science][Medline].
  • Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382:685-691[Medline].
  • Yang DS, Small DH, Seydel U, Smith JD, Hallmayer J, Gandy SE, Martins RN (1999) Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience 90:1217-1226[Web of Science][Medline].
  • Yazawa H, Yu ZX, Takeda, Le Y, Gong W, Ferrans VJ, Oppenheim JJ, Li CC, Wang JM (2001) Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J 15:2454-2462[Abstract/Free Full Text].
  • Zhan S, Beyreuther K, Schmitt H (1993) Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neurodegenerative disorders with dementia. Dementia 4:66-74[Medline].
  • Zhuo M, Holtzman DM, Li Y, Osaka H, DeMaro J, Jacquin M, Bu G (2000) Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J Neurosci 20:542-549[Abstract/Free Full Text].

Copyright © 2002 Society for Neuroscience  0270-6474/02/22219298-07$05.00/0


This article has been cited by other articles:


Home page
 J. Neurosci.Home page
I. Y. Tamboli, K. Prager, D. R. Thal, K. M. Thelen, I. Dewachter, C. U. Pietrzik, P. St. George-Hyslop, S. S. Sisodia, B. De Strooper, M. T. Heneka, et al.
Loss of {gamma}-Secretase Function Impairs Endocytosis of Lipoprotein Particles and Membrane Cholesterol Homeostasis
J. Neurosci., November 12, 2008; 28(46): 12097 - 12106.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
K.-J. Yin, J. R. Cirrito, P. Yan, X. Hu, Q. Xiao, X. Pan, R. Bateman, H. Song, F.-F. Hsu, J. Turk, et al.
Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-beta Peptide Catabolism
J. Neurosci., October 25, 2006; 26(43): 10939 - 10948.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
L. Esposito, J. Raber, L. Kekonius, F. Yan, G.-Q. Yu, N. Bien-Ly, J. Puolivali, K. Scearce-Levie, E. Masliah, and L. Mucke
Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice.
J. Neurosci., May 10, 2006; 26(19): 5167 - 5179.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Krawitz, C. Haffner, R. Fluhrer, H. Steiner, B. Schmid, and C. Haass
Differential Localization and Identification of a Critical Aspartate Suggest Non-redundant Proteolytic Functions of the Presenilin Homologues SPPL2b and SPPL3
J. Biol. Chem., November 25, 2005; 280(47): 39515 - 39523.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. D. Fryer, R. B. DeMattos, L. M. McCormick, M. A. O'Dell, M. L. Spinner, K. R. Bales, S. M. Paul, P. M. Sullivan, M. Parsadanian, G. Bu, et al.
The Low Density Lipoprotein Receptor Regulates the Level of Central Nervous System Human and Murine Apolipoprotein E but Does Not Modify Amyloid Plaque Pathology in PDAPP Mice
J. Biol. Chem., July 8, 2005; 280(27): 25754 - 25759.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. V. Zerbinatti, D. F. Wozniak, J. Cirrito, J. A. Cam, H. Osaka, K. R. Bales, M. Zhuo, S. M. Paul, D. M. Holtzman, and G. Bu
Increased soluble amyloid-{beta} peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein
PNAS, January 27, 2004; 101(4): 1075 - 1080.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (29)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Uden, E.
Right arrow Articles by Masliah, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Uden, E.
Right arrow Articles by Masliah, E.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
Medline Plus Health Information
*Degenerative Nerve Diseases

-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help
-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-